1
|
Lima AR, Ferreira BM, Zhang C, Jolly A, Du H, White JJ, Dawood M, Lins TC, Chiabai MA, van Beusekom E, Cordoba MS, Caldas Rosa EC, Kayserili H, Kimonis V, Wu E, Mellado C, Aggarwal V, Richieri‐Costa A, Brunoni D, Canó TM, Jorge AAL, Kim CA, Honjo R, Bertola DR, Dandalo‐Girardi RM, Bayram Y, Gezdirici A, Yilmaz‐Gulec E, Gumus E, Yilmaz GC, Okamoto N, Ohashi H, Coban–Akdemir Z, Mitani T, Jhangiani SN, Muzny DM, Regattieri NA, Pogue R, Pereira RW, Otto PA, Gibbs RA, Ali BR, van Bokhoven H, Brunner HG, Sutton VR, Lupski JR, Vianna‐Morgante AM, Carvalho CMB, Mazzeu JF. Back Cover, Volume 43, Issue 7. Hum Mutat 2022. [DOI: 10.1002/humu.24420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Ariadne R. Lima
- Programa de Pós‐Graduação em Ciências da Saúde Universidade de Brasília Brasília DF Brasil
| | - Barbara M. Ferreira
- Programa de Pós‐Graduação em Ciências Médicas Universidade de Brasília Brasília DF Brasil
| | - Chaofan Zhang
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
| | - Angad Jolly
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Medical Scientist Training Program Baylor College of Medicine Houston Texas USA
| | - Haowei Du
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
| | - Janson J. White
- Department of Pediatrics University of Washington Seattle Washington USA
| | - Moez Dawood
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Medical Scientist Training Program Baylor College of Medicine Houston Texas USA
- Human Genome Sequencing Center, Baylor College of Medicine Houston Texas USA
| | - Tulio C. Lins
- Programa de Pós‐graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília Brasília DF Brasil
| | - Marcela A. Chiabai
- Programa de Pós‐graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília Brasília DF Brasil
| | | | - Mara S. Cordoba
- Faculdade de Medicina Universidade de Brasília Brasília DF Brasil
- Hospital Universitário de Brasília Brasília Brasil
| | - Erica C.C. Caldas Rosa
- Programa de Pós‐Graduação em Ciências da Saúde Universidade de Brasília Brasília DF Brasil
| | - Hulya Kayserili
- Medical Genetics Department, School of Medicine (KUSoM) Koç University Istanbul Turkey
| | - Virginia Kimonis
- Division of Genetics and Genomic Medicine, Department of Pediatrics University of California‐Irvine Irvine California USA
| | - Erica Wu
- Obstetrics and Gynecology Stanford University Stanford California USA
| | - Cecilia Mellado
- Unidad de Genética, División de Pediatría Pontificia Universidad Católica de Chile Santiago Chile
| | - Vineet Aggarwal
- Department of Orthopedics Indira Gandhi Medical College Snowdon India
| | | | - Décio Brunoni
- Universidade Presbiteriana Mackenzie–UPM São Paulo Brasil
| | - Talyta M. Canó
- Programa de Pós‐Graduação em Ciências Médicas Universidade de Brasília Brasília DF Brasil
- Núcleo de Genética–SESDF Brasília DF Brasil
| | - Alexander A. L. Jorge
- Laboratório de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo Unidade de Endocrinologia Genética São Paulo Brasil
| | - Chong A. Kim
- Unidade de Genética, Instituto da Criança‐Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de São Paulo São Paulo Brasil
| | - Rachel Honjo
- Unidade de Genética, Instituto da Criança‐Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de São Paulo São Paulo Brasil
| | - Débora R. Bertola
- Unidade de Genética, Instituto da Criança‐Hospital das Clinicas HCFMUSP, Faculdade de Medicina Universidade de São Paulo São Paulo Brasil
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências Universidade de São Paulo São Paulo Brasil
| | - Raissa M. Dandalo‐Girardi
- Programa de Mestrado Profissional em Aconselhamento Genético e Genômica Humana, Instituto de Biociências Universidade de São Paulo São Paulo Brasil
| | - Yavuz Bayram
- Department of Pathology and Laboratory Medicine, Division of Genomic Diagnostics Children's Hospital of Philadelphia Philadelphia Pennsylvania USA
- Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
| | - Alper Gezdirici
- Department of Medical Genetics Basaksehir Cam and Sakura City Hospital Istanbul Turkey
| | | | - Evren Gumus
- Medical Genetics Department Medicine Faculty Mugla Sitki Kocman University Mugla Turkey
| | - Gülay C. Yilmaz
- Medical Genetics Department Medicine Faculty Mugla Sitki Kocman University Mugla Turkey
| | - Nobuhiko Okamoto
- Department of Medical Genetics Osaka Women's and Children's Hospital Osaka Japan
| | - Hirofumi Ohashi
- Saitama Children's Medical Center, Division of Medical Genetics Saitama Japan
| | - Zeynep Coban–Akdemir
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Department of Epidemiology, Human Genetics, and Environmental Sciences, Human Genetics Center School of Public Health, UT Health Houston Texas USA
| | - Tadahiro Mitani
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
| | | | - Donna M. Muzny
- Human Genome Sequencing Center, Baylor College of Medicine Houston Texas USA
| | | | - Robert Pogue
- Programa de Pós‐graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília Brasília DF Brasil
| | - Rinaldo W. Pereira
- Programa de Pós‐graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília Brasília DF Brasil
| | - Paulo A. Otto
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências Universidade de São Paulo São Paulo Brasil
| | - Richard A. Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine Houston Texas USA
| | - Bassam R. Ali
- Department of Genetics and Genomics, College of Medicine and Health Sciences United Arab Emirates University Al‐Ain United Arab Emirates
| | | | - Han G. Brunner
- Radboud University Nijmegen Medical Centre Nijmegen The Netherlands
| | - V. Reid Sutton
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Texas Children's Hospital Houston Texas USA
| | - James R. Lupski
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Human Genome Sequencing Center, Baylor College of Medicine Houston Texas USA
- Texas Children's Hospital Houston Texas USA
- Department of Pediatrics Baylor College of Medicine Houston Texas USA
| | - Angela M. Vianna‐Morgante
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências Universidade de São Paulo São Paulo Brasil
| | - Claudia M. B. Carvalho
- Department of Molecular and Human Genetics Baylor College of Medicine Houston Texas USA
- Pacific Northwest Research Institute Seattle Washington USA
| | - Juliana F. Mazzeu
- Programa de Pós‐Graduação em Ciências da Saúde Universidade de Brasília Brasília DF Brasil
- Programa de Pós‐Graduação em Ciências Médicas Universidade de Brasília Brasília DF Brasil
- Faculdade de Medicina Universidade de Brasília Brasília DF Brasil
- Robinow Syndrome Foundation Anoka Minnesota USA
| |
Collapse
|
2
|
Lima AR, Ferreira BM, Zhang C, Jolly A, Du H, White JJ, Dawood M, Lins TC, Chiabai MA, van Beusekom E, Cordoba MS, Caldas Rosa ECC, Kayserili H, Kimonis V, Wu E, Mellado C, Aggarwal V, Richieri-Costa A, Brunoni D, Canó TM, Jorge AAL, Kim CA, Honjo R, Bertola DR, Dandalo-Girardi RM, Bayram Y, Gezdirici A, Yilmaz-Gulec E, Gumus E, Yilmaz GC, Okamoto N, Ohashi H, Coban-Akdemir Z, Mitani T, Jhangiani SN, Muzny DM, Regattieri NAP, Pogue R, Pereira RW, Otto PA, Gibbs RA, Ali BR, van Bokhoven H, Brunner HG, Reid Sutton V, Lupski JR, Vianna-Morgante AM, Carvalho CMB, Mazzeu JF. Phenotypic and mutational spectrum of ROR2-related Robinow syndrome. Hum Mutat 2022; 43:900-918. [PMID: 35344616 DOI: 10.1002/humu.24375] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 03/23/2022] [Accepted: 03/24/2022] [Indexed: 02/05/2023]
Abstract
Robinow syndrome is characterized by a triad of craniofacial dysmorphisms, disproportionate-limb short stature and genital hypoplasia. A significant degree of phenotypic variability seems to correlate with different genes/loci. Disturbances of the non-canonical WNT-pathway have been identified as the main cause of the syndrome. Biallelic variants in ROR2 cause an autosomal recessive form of the syndrome with distinctive skeletal findings. Twenty-two patients with a clinical diagnosis of autosomal recessive Robinow syndrome were screened for variants in ROR2 using multiple molecular approaches. We identified 25 putatively pathogenic ROR2 variants, 16 novel, including single nucleotide variants and exonic deletions. Detailed phenotypic analyses revealed that all subjects presented with a prominent forehead, hypertelorism, short nose, abnormality of the nasal tip, brachydactyly, mesomelic limb shortening, short stature and genital hypoplasia in male patients. A total of 19 clinical features were present in more than 75% of the subjects, thus pointing to an overall uniformity of the phenotype. Disease-causing variants in ROR2, contribute to a clinically recognizable AR trait phenotype with multiple skeletal defects. A comprehensive quantitative clinical evaluation this cohort delineated the phenotypic spectrum of ROR2-related Robinow syndrome. The identification of exonic deletion variant alleles further supports the contention of a loss-of-function mechanism in the etiology of the syndrome. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Ariadne R Lima
- Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brasil
| | - Barbara M Ferreira
- Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, DF, Brasil
| | - Chaofan Zhang
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - Angad Jolly
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, USA
| | - Haowei Du
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - Janson J White
- Department of Pediatrics, University of Washington, Seattle, WA, USA
| | - Moez Dawood
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Medical Scientist Training Program, Baylor College of Medicine, Houston, TX, USA.,Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - Tulio C Lins
- Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brasil
| | - Marcela A Chiabai
- Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brasil
| | | | - Mara S Cordoba
- Faculdade de Medicina, Universidade de Brasília, Brasília, DF, Brasil.,Hospital Universitário de Brasília, Brasília, Brasil
| | - Erica C C Caldas Rosa
- Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brasil
| | - Hulya Kayserili
- Koç University, School of Medicine (KUSoM), Medical Genetics Department, Istanbul, Turkey
| | - Virginia Kimonis
- Division of Genetics and Genomic Medicine, Dept. of Pediatrics, University of California-Irvine, Irvine, CA, USA
| | - Erica Wu
- Stanford University, Obstetrics and Gynecology, Stanford, CA, USA
| | - Cecilia Mellado
- Unidad de Genética, División de Pediatría, Pontificia Universidad Católica de Chile, Santiago, Chile
| | - Vineet Aggarwal
- Department of Orthopedics, Indira Gandhi Medical College, Snowdon, Shimla-1, India
| | | | - Décio Brunoni
- Universidade Presbiteriana Mackenzie - UPM, São Paulo, SP, Brasil
| | - Talyta M Canó
- Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, DF, Brasil.,Núcleo de Genética - SESDF, Brasília, DF, Brasil
| | - Alexander A L Jorge
- Unidade de Endocrinologia Genética, Laboratório de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil
| | - Chong A Kim
- Unidade de Genética, Instituto da Criança - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Rachel Honjo
- Unidade de Genética, Instituto da Criança - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Débora R Bertola
- Unidade de Endocrinologia Genética, Laboratório de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brasil.,Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Raissa M Dandalo-Girardi
- Programa de Mestrado Profissional em Aconselhamento Genético e Genômica Humana, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Yavuz Bayram
- Division of Genomic Diagnostics, Department of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA.,Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
| | - Alper Gezdirici
- Department of Medical Genetics, Basaksehir Cam and Sakura City Hospital, Istanbul, Turkey
| | | | - Evren Gumus
- Medical Genetics Department, Medicine Faculty, Mugla Sitki Kocman University, Mugla, Turkey
| | - Gülay C Yilmaz
- Medical Genetics Department, Medicine Faculty, Mugla Sitki Kocman University, Mugla, Turkey
| | - Nobuhiko Okamoto
- Department of Medical Genetics, Osaka Women's and Children's Hospital, Osaka, Japan
| | - Hirofumi Ohashi
- Division of Medical Genetics, Saitama Children's Medical Center, Saitama, 330-8777, Japan
| | - Zeynep Coban-Akdemir
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Human Genetics Center, Department of Epidemiology, Human Genetics, and Environmental Sciences, School of Public Health, UT Health, Houston, TX, USA
| | - Tadahiro Mitani
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA
| | - Shalini N Jhangiani
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - Donna M Muzny
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | | | - Robert Pogue
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - Rinaldo W Pereira
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - Paulo A Otto
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Richard A Gibbs
- Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA
| | - Bassam R Ali
- Department of Genetics and Genomics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
| | - Hans van Bokhoven
- Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brasil
| | - Han G Brunner
- Programa de Pós-graduação em Ciências Genômicas e Biotecnologia, Universidade Católica de Brasília, Brasília, DF, Brasil
| | - V Reid Sutton
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Hospital, Houston, TX, USA
| | - James R Lupski
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Human Genome Sequencing Center, Baylor College of Medicine, Houston, TX, USA.,Texas Children's Hospital, Houston, TX, USA.,Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
| | - Angela M Vianna-Morgante
- Departamento de Genética e Biologia Evolutiva, Instituto de Biociências, Universidade de São Paulo, São Paulo, SP, Brasil
| | - Claudia M B Carvalho
- Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.,Pacific Northwest Research Institute, Seattle, WA, USA
| | - Juliana F Mazzeu
- Programa de Pós-Graduação em Ciências da Saúde, Universidade de Brasília, Brasília, DF, Brasil.,Programa de Pós-Graduação em Ciências Médicas, Universidade de Brasília, Brasília, DF, Brasil.,Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.,Robinow Syndrome Foundation, Anoka, MN, USA
| |
Collapse
|
3
|
Linnenkamp B, Girardi R, Rocha L, Yamamoto G, Ceroni JR, Mendes AEC, Honjo R, Oliveira LA, Amemiya RB, Quaio C, de Oliveira Filho JB, Kim CA, Bertola D. Vertebral segmentation defects in a Brazilian cohort: Clinical and molecular analysis focused on spondylocostal dysostosis. Clin Genet 2022; 101:476-478. [PMID: 35137400 DOI: 10.1111/cge.14118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 01/18/2022] [Accepted: 01/20/2022] [Indexed: 11/30/2022]
Affiliation(s)
| | - Raissa Girardi
- Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil
| | - Letícia Rocha
- Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil
| | - Guilherme Yamamoto
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.,Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil
| | - José Ricardo Ceroni
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.,Laboratório Clínico, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | | | - Rachel Honjo
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil
| | | | | | - Caio Quaio
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.,Laboratório Clínico, Hospital Israelita Albert Einstein, São Paulo, Brazil
| | | | - Chong Ae Kim
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil
| | - Débora Bertola
- Hospital das Clínicas, Universidade de São Paulo, São Paulo, Brazil.,Instituto de Biociências, Universidade de São Paulo, São Paulo, Brazil
| |
Collapse
|
4
|
Homma TK, Freire BL, Honjo R, Dauber A, Funari MFA, Lerario AM, Albuquerque EVA, Vasques GA, Bertola DR, Kim CA, Malaquias AC, Jorge AAL. Growth and Clinical Characteristics of Children with Floating-Harbor Syndrome: Analysis of Current Original Data and a Review of the Literature. Horm Res Paediatr 2020; 92:115-123. [PMID: 31715605 DOI: 10.1159/000503782] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2019] [Accepted: 09/28/2019] [Indexed: 11/19/2022] Open
Abstract
BACKGROUND Floating-Harbor syndrome (FHS) is a rare condition characterized by dysmorphic facial features, short stature, and expressive language delay. OBJECTIVE The aim of this study was to describe a cohort of patients with FHS and review the literature about the response to recombinant human growth hormone (rhGH) therapy. METHODS Anthropometric and laboratory data from 7 patients with FHS were described. The molecular diagnosis was established by multigene analysis. Moreover, we reviewed the literature concerning patients with FHS treated with rhGH. RESULTS All 7 patients were born small for gestational age. At first evaluation, 6 patients had a height standard deviation score (SDS) ≤-2 and 1 had short stature in relation to their target height. Bone age was usually delayed, which rapidly advanced during puberty. Nonspecific skeletal abnormalities were frequently noticed, and normal to elevated plasma IGF-I levels were observed in all except 1 patient with growth hormone deficiency. Information about 20 patients with FHS treated with rhGH was analyzed (4 from our cohort and 16 from the literature). The median height changes during the treatment period (approx. 2.9 years) were 1.1 SDS (range from -0.4 to 3.1). Nontreated patients had an adult height SDS of -4.1 ± 1.2 (n = 10) versus -2.6 ± 0.8 SDS (n = 7, p 0.012) for treated patients. CONCLUSION We observed a laboratory profile compatible with IGF-1 insensitivity in some patients with FHS. Nevertheless, our study suggests that children with FHS may be considered as candidates for rhGH therapy. Further studies are necessary to establish the real benefit and safety of rhGH therapy in these patients.
Collapse
Affiliation(s)
- Thais K Homma
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.,Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil
| | - Bruna L Freire
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.,Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil
| | - Rachel Honjo
- Unidade de Genetica do Instituto da Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Andrew Dauber
- Division of Endocrinology, Children's National Health System, Washington, District of Columbia, USA
| | - Mariana F A Funari
- Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil
| | - Antonio M Lerario
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, Michigan, USA
| | - Edoarda V A Albuquerque
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil
| | - Gabriela A Vasques
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil
| | - Debora R Bertola
- Unidade de Genetica do Instituto da Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Chong A Kim
- Unidade de Genetica do Instituto da Criança, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil
| | - Alexsandra C Malaquias
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil.,Unidade de Endocrinologia Pediatrica, Departamento de Pediatria, Irmandade da Santa Casa de Misericórdia de São Paulo, Faculdade de Ciências Médicas da Santa Casa de São Paulo, Sao Paulo, Brazil
| | - Alexander A L Jorge
- Unidade de Endocrinologia Genetica, Laboratorio de Endocrinologia Celular e Molecular LIM25, Disciplina de Endocrinologia da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil, .,Unidade de Endocrinologia do Desenvolvimento, Laboratorio de Hormonios e Genetica Molecular LIM42, Hospital das Clínicas da Faculdade de Medicina da Universidade de Sao Paulo (FMUSP), Sao Paulo, Brazil,
| |
Collapse
|
5
|
Carvalho E, Honjo R, Magalhães M, Yamamoto G, Rocha K, Naslavsky M, Zatz M, Passos-Bueno MR, Kim C, Bertola D. Schinzel-Giedion syndrome in two Brazilian patients: Report of a novel mutation in SETBP1 and literature review of the clinical features. Am J Med Genet A 2015; 167A:1039-46. [PMID: 25663181 DOI: 10.1002/ajmg.a.36789] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2014] [Accepted: 08/29/2014] [Indexed: 11/06/2022]
Abstract
Schinzel-Giedion syndrome is a rare autosomal dominant disorder comprising postnatal growth failure, profound developmental delay, seizures, facial dysmorphisms, genitourinary, skeletal, neurological, and cardiac defects. It was recently revealed that Schinzel-Giedion syndrome is caused by de novo mutations in SETBP1, but there are few reports of this syndrome with molecular confirmation. We describe two unrelated Brazilian patients with Schinzel-Giedion syndrome, one of them carrying a novel mutation. We also present a review of clinical manifestations of the syndrome, comparing our cases to patients reported in literature emphasizing the importance of the facial gestalt associated with neurological involvement for diagnostic suspicion of this syndrome.
Collapse
Affiliation(s)
- Ellaine Carvalho
- Genetics Unit, Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
| | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Pereira FDS, Matte U, Habekost CT, de Castilhos RM, El Husny AS, Lourenço CM, Vianna-Morgante AM, Giuliani L, Galera MF, Honjo R, Kim CA, Politei J, Vargas CR, Jardim LB. Mutations, clinical findings and survival estimates in South American patients with X-linked adrenoleukodystrophy. PLoS One 2012; 7:e34195. [PMID: 22479560 PMCID: PMC3315551 DOI: 10.1371/journal.pone.0034195] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2011] [Accepted: 02/25/2012] [Indexed: 12/13/2022] Open
Abstract
UNLABELLED In this study, we analyzed the ABCD1 gene in X-linked adrenoleukodystrophy (X-ALD) patients and relatives from 38 unrelated families from South America, as well as phenotypic proportions, survival estimates, and the potential effect of geographical origin in clinical characteristics. METHODS X- ALD patients from Brazil, Argentina and Uruguay were invited to participate in molecular studies to determine their genetic status, characterize the mutations and improve the genetic counseling of their families. All samples were screened by SSCP analysis of PCR fragments, followed by automated DNA sequencing to establish the specific mutation in each family. Age at onset and at death, male phenotypes, genetic status of women, and the effect of family and of latitude of origin were also studied. RESULTS We identified thirty-six different mutations (twelve novel). This population had an important allelic heterogeneity, as only p.Arg518Gln was repeatedly found (three families). Four cases carried de novo mutations. Intra-familiar phenotype variability was observed in all families. Out of 87 affected males identified, 65% had the cerebral phenotype (CALD). The mean (95% CI) ages at onset and at death of the CALD were 10.9 (9.1-12.7) and 24.7 (19.8-29.6) years. No association was found between phenotypic manifestations and latitude of origin. One index-case was a girl with CALD who carried an ABCD1 mutation, and had completely skewed X inactivation. CONCLUSIONS This study extends the spectrum of mutations in X-ALD, confirms the high rates of de novo mutations and the absence of common mutations, and suggests a possible high frequency of cerebral forms in our population.
Collapse
Affiliation(s)
- Fernanda dos Santos Pereira
- Gene Therapy Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Post-Graduation Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Ursula Matte
- Gene Therapy Center, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Post-Graduation Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Clarissa Troller Habekost
- Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Post-Graduation Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Raphael Machado de Castilhos
- Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Post-Graduation Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | | | | | - Angela M. Vianna-Morgante
- Department of Genetics and Evolutionary Biology, Institute of Biosciences, Universidade de São Paulo, São Paulo, Brazil
| | - Liane Giuliani
- Department of Pediatrics, Universidade Federal do Mato Grosso do Sul, Campo Grande, Brazil
| | | | - Rachel Honjo
- Department of Genetics, Children Institute, Universidade de São Paulo, São Paulo, Brazil
| | - Chong Ae Kim
- Department of Genetics, Children Institute, Universidade de São Paulo, São Paulo, Brazil
| | - Juan Politei
- Neuromuscular Disorders and Neuropathic Pain Section, Neurology Department, Hospital Juan A. Fernández, Buenos Aires, Argentina
| | - Carmen Regla Vargas
- Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Department of Analysis, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| | - Laura Bannach Jardim
- Medical Genetics Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
- Post-Graduation Program in Medical Sciences, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Post-Graduation Program in Genetics and Molecular Biology, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
- Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil
| |
Collapse
|
7
|
Giugliani R, Federhen A, Muñoz Rojas MV, Vieira TA, Artigalás O, Pinto LLC, Azevedo AC, Acosta AX, Bomfim C, Lourenço CM, Kim CA, Horovitz D, Souza DB, Norato D, Marinho D, Palhares D, Santos ES, Ribeiro E, Valadares ER, Guarany F, De Lucca GR, Pimentel H, Souza IND, Corrêa Neto J, Fraga JC, Góes JE, Cabral JM, Simeonato J, Llerena JC, Jardim LB, Giuliani LDR, Silva LCSD, Santos M, Moreira MA, Kerstenetzky M, Ribeiro M, Ruas N, Barrios P, Aranda P, Honjo R, Boy R, Costa R, Souza CFMD, Alcântara FF, Avilla SGA, Fagondes S, Martins AM. [Enzyme replacement therapy for mucopolysaccharidoses I, II and VI: recommendations from a group of Brazilian F experts]. Rev Assoc Med Bras (1992) 2011; 56:271-7. [PMID: 20676532 DOI: 10.1590/s0104-42302010000300009] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Mucopolysaccharidoses (MPS) are rare genetic diseases caused by deficiency of specific lysosomal enzymes that affect catabolism of glycosaminoglycans (GAG). Accumulation of GAG in various organs and tissues in MPS patients results in a series of signs and symptoms, producing a multisystemic condition affecting bones and joints, the respiratory and cardiovascular systems and many other organs and tissues, including in some cases, cognitive performance. So far, eleven enzyme defects that cause seven different types of MPS have been identified. Before introduction of therapies to restore deficient enzyme activity, treatment of MPS focused primarily on prevention and care of complications, still a very important aspect in the management of these patients. In the 80's treatment of MPS with bone marrow transplantation/hematopoietic stem cells transplantation (BMT/HSCT) was proposed and in the 90's, enzyme replacement therapy (ERT),began to be developed and was approved for clinical use in MPS I, II and VI in the first decade of the 21st century. The authors of this paper are convinced that a better future for patients affected by mucopolysaccharidoses depends upon identifying, understanding and appropriately managing the multisystemic manifestations of these diseases. This includes the provision of support measures (which should be part of regular multidisciplinary care of these patients) and of specific therapies. Although inhibition of synthesis of GAG and the recovery of enzyme activity with small molecules also may play a role in the management of MPS, the breakthrough is the currently available intravenous ERT. ERT radically changed the setting for treatment of mucopolysaccharidosis I, II and VI in the last decade., Benefits can even be extended soon to MPS IV A (ERT for this condition is already in clinical development), with prediction for treatment of MPS III A and the cognitive deficit in MPS II by administration of the enzyme directly into the central nervous system (CNS). A large number of Brazilian services, from all regions of the country, already have experience with ERT for MPS I, II and VI. This experience was gained not only by treating patients but also with the participation of some groups in clinical trials involving ERT for these conditions. Summing up the three types of MPS, more than 250 patients have already been treated with ERT in Brazil. The experience of professionals coupled to the data available in international literature, allowed us to elaborate this document, produced with the goal of bringing together and harmonize the information available for the treatment of these severe and progressive diseases, which, fortunately, are now treatable, a situation which bring new perspectives for Brazilian patients, affected by these conditions.
Collapse
|
8
|
Giugliani R, Federhen A, Rojas MVM, Vieira T, Artigalás O, Pinto LL, Azevedo AC, Acosta A, Bonfim C, Lourenço CM, Kim CA, Horovitz D, Bonfim D, Norato D, Marinho D, Palhares D, Santos ES, Ribeiro E, Valadares E, Guarany F, de Lucca GR, Pimentel H, de Souza IN, Correa J, Fraga JC, Goes JE, Cabral JM, Simionato J, Llerena J, Jardim L, Giuliani L, da Silva LCS, Santos ML, Moreira MA, Kerstenetzky M, Ribeiro M, Ruas N, Barrios P, Aranda P, Honjo R, Boy R, Costa R, Souza C, Alcantara FF, Avilla SGA, Fagondes S, Martins AM. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol 2010; 33:589-604. [PMID: 21637564 PMCID: PMC3036139 DOI: 10.1590/s1415-47572010005000093] [Citation(s) in RCA: 127] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2010] [Accepted: 04/30/2010] [Indexed: 12/20/2022] Open
Abstract
Mucopolysaccharidoses (MPS) are rare genetic diseases caused by the deficiency of one of the lysosomal enzymes involved in the glycosaminoglycan (GAG) breakdown pathway. This metabolic block leads to the accumulation of GAG in various organs and tissues of the affected patients, resulting in a multisystemic clinical picture, sometimes including cognitive impairment. Until the beginning of the XXI century, treatment was mainly supportive. Bone marrow transplantation improved the natural course of the disease in some types of MPS, but the morbidity and mortality restricted its use to selected cases. The identification of the genes involved, the new molecular biology tools and the availability of animal models made it possible to develop specific enzyme replacement therapies (ERT) for these diseases. At present, a great number of Brazilian medical centers from all regions of the country have experience with ERT for MPS I, II, and VI, acquired not only through patient treatment but also in clinical trials. Taking the three types of MPS together, over 200 patients have been treated with ERT in our country. This document summarizes the experience of the professionals involved, along with the data available in the international literature, bringing together and harmonizing the information available on the management of these severe and progressive diseases, thus disclosing new prospects for Brazilian patients affected by these conditions.
Collapse
|
9
|
Teixeira C, Silva C, Honjo R, Bertola D, Albano L, Kim C. Dental evaluation of Kabuki syndrome (KS) patients. Cleft Palate Craniofac J 2009. [DOI: 10.1597/08-077] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
10
|
Furquim I, Honjo R, Bae R, Andrade W, Santos M, Tannuri U, Kim C. Proteus syndrome: report of a case with recurrent abdominal lipomatosis. J Pediatr Surg 2009; 44:E1-3. [PMID: 19361616 DOI: 10.1016/j.jpedsurg.2008.12.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2008] [Revised: 12/04/2008] [Accepted: 12/05/2008] [Indexed: 11/17/2022]
Abstract
Proteus syndrome (PS) is an extremely rare congenital hamartomatous syndrome that was first delineated by Cohen and Hayden (1). The estimated prevalence is less than 1 per 1,000,000 live births (2). It is a sporadic disorder that causes overgrowth of multiple tissues, especially bone, fat, and other connective tissues in a patchy or mosaic pattern. Subcutaneous as well as internal lipomas that may grow to an enormous size are frequently observed. Nevertheless, among the internal lipomas, abdominal lipomatosis is rare (3), with less than 15 cases reported. Herein, we report the first patient described with this distinctive syndrome associated with lipomatosis involving the epiploon.
Collapse
|
11
|
Kim CA, Honjo R, Bertola D, Albano L, Oliveira L, Jales S, Siqueira J, Castilho A, Balemans W, Piters E, Jennes K, Van Hul W. A Known SOST Gene Mutation Causes Sclerosteosis in a Familial and an Isolated Case from Brazilian Origin. ACTA ACUST UNITED AC 2008; 12:475-9. [DOI: 10.1089/gte.2008.0036] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Affiliation(s)
- Chong Ae Kim
- Clinical Genetics Unit, Instituto da Criança, Hospital das Clínicas, USP, São Paulo, Brazil
| | - Rachel Honjo
- Clinical Genetics Unit, Instituto da Criança, Hospital das Clínicas, USP, São Paulo, Brazil
| | - Débora Bertola
- Clinical Genetics Unit, Instituto da Criança, Hospital das Clínicas, USP, São Paulo, Brazil
| | - Lílian Albano
- Clinical Genetics Unit, Instituto da Criança, Hospital das Clínicas, USP, São Paulo, Brazil
| | - Luiz Oliveira
- Clinical Genetics Unit, Instituto da Criança, Hospital das Clínicas, USP, São Paulo, Brazil
| | | | | | | | - Wendy Balemans
- Department of Medical Genetics, University of Antwerp, Antwerp, Belgium
| | - Elke Piters
- Department of Medical Genetics, University of Antwerp, Antwerp, Belgium
| | - Karen Jennes
- Department of Medical Genetics, University of Antwerp, Antwerp, Belgium
| | - Wim Van Hul
- Department of Medical Genetics, University of Antwerp, Antwerp, Belgium
| |
Collapse
|
12
|
Yamamoto K, Honjo R, Sekine T. Fluorometric studies on the light chains of skeletal muscle myosin. III. Effect of Ca2+ on the reactivity of two SH groups of DTNB light chain in myosin and in the isolated state. J Biochem 1980; 87:213-7. [PMID: 7358630 DOI: 10.1093/oxfordjournals.jbchem.a132727] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023] Open
Abstract
We studied the effect of Ca2+ on the reactivities of two SH groups of DTNB light chain (Cys 128 and Cys 157) using a fluorogenic thiol reagent. It was found that a Ca2+-induced change in reactivity occurred only with Cys 128 when the light chain was in an isolated state, whereas it occurred with both Cys 128 and Cys 157 when the light chain was incorporated in myosin. These results indicate that the Ca2+-induced change in the conformation of DTNB light chain in the isolated state was different from that of the light chain in myosin. It may therefore be difficult to relate the Ca2+-induced conformational change observed in the isolated DTNB light chain to the molecular mechanism of myosin-linked Ca2+ regulation.
Collapse
|